AstraZeneca Pharma India Limited (APIL) is a 90% subsidiary of the UK based AstraZeneca Pharmaceuticals, which is one of the world's leading pharma companies. APIL has interests in the six crucial areas of cardiovascular, respiratory, maternal health... More
Biocon is India's largest biotechnology company with presence in biopharmaceuticals, custom research and clinical research. It started as an enzymes manufacturer and later evolved into an integrated biopharmaceutical company. The company has two subs... More
ASTRAZENECA PHARMA | BIOCON | ASTRAZENECA PHARMA/ BIOCON |
|||
---|---|---|---|---|---|
P/E (TTM) | x | 129.7 | 31.6 | 410.3% | View Chart |
P/BV | x | 36.4 | 3.8 | 966.7% | View Chart |
Dividend Yield | % | 0.0 | 0.3 | - |
![]() ![]() |
EQUITY SHARE DATA | |||||
---|---|---|---|---|---|
ASTRAZENECA PHARMA Mar-18 |
BIOCON Mar-19 |
ASTRAZENECA PHARMA/ BIOCON |
5-Yr Chart Click to enlarge
|
||
High | Rs | 1,278 | 707 | 180.7% | |
Low | Rs | 883 | 554 | 159.4% | |
Sales per share (Unadj.) | Rs | 228.4 | 91.9 | 248.5% | |
Earnings per share (Unadj.) | Rs | 10.4 | 16.7 | 62.0% | |
Cash flow per share (Unadj.) | Rs | 16.3 | 24.2 | 67.3% | |
Dividends per share (Unadj.) | Rs | 0 | 1.00 | 0.0% | |
Dividend yield (eoy) | % | 0 | 0.2 | 0.0% | |
Book value per share (Unadj.) | Rs | 98.8 | 101.6 | 97.2% | |
Shares outstanding (eoy) | m | 25.00 | 600.00 | 4.2% | |
Bonus/Rights/Conversions | - | - | - | ||
Price / Sales ratio | x | 4.7 | 6.9 | 68.9% | |
Avg P/E ratio | x | 104.2 | 37.7 | 276.2% | |
P/CF ratio (eoy) | x | 66.4 | 26.1 | 254.7% | |
Price / Book Value ratio | x | 10.9 | 6.2 | 176.3% | |
Dividend payout | % | 0 | 6.0 | 0.0% | |
Avg Mkt Cap | Rs m | 27,008 | 378,330 | 7.1% | |
No. of employees | `000 | 1.4 | 6.1 | 22.1% | |
Total wages/salary | Rs m | 1,535 | 11,653 | 13.2% | |
Avg. sales/employee | Rs Th | 4,210.9 | 8,994.3 | 46.8% | |
Avg. wages/employee | Rs Th | 1,132.2 | 1,900.7 | 59.6% | |
Avg. net profit/employee | Rs Th | 191.1 | 1,635.3 | 11.7% |
INCOME DATA | |||||
---|---|---|---|---|---|
Net Sales | Rs m | 5,710 | 55,144 | 10.4% | |
Other income | Rs m | 123 | 1,444 | 8.5% | |
Total revenues | Rs m | 5,833 | 56,588 | 10.3% | |
Gross profit | Rs m | 463 | 15,883 | 2.9% | |
Depreciation | Rs m | 147 | 4,478 | 3.3% | |
Interest | Rs m | 0 | 709 | 0.0% | |
Profit before tax | Rs m | 438 | 12,140 | 3.6% | |
Minority Interest | Rs m | 0 | 9 | 0.0% | |
Prior Period Items | Rs m | 0 | 0 | - | |
Extraordinary Inc (Exp) | Rs m | 0 | 0 | - | |
Tax | Rs m | 179 | 2,123 | 8.4% | |
Profit after tax | Rs m | 259 | 10,026 | 2.6% | |
Gross profit margin | % | 8.1 | 28.8 | 28.1% | |
Effective tax rate | % | 40.8 | 17.5 | 233.6% | |
Net profit margin | % | 4.5 | 18.2 | 25.0% |
BALANCE SHEET DATA | |||||
---|---|---|---|---|---|
Current assets | Rs m | 3,209 | 48,228 | 6.7% | |
Current liabilities | Rs m | 2,070 | 30,376 | 6.8% | |
Net working cap to sales | % | 20.0 | 32.4 | 61.7% | |
Current ratio | x | 1.6 | 1.6 | 97.7% | |
Inventory Days | Days | 72 | 68 | 105.9% | |
Debtors Days | Days | 35 | 86 | 40.8% | |
Net fixed assets | Rs m | 790 | 64,130 | 1.2% | |
Share capital | Rs m | 50 | 3,000 | 1.7% | |
"Free" reserves | Rs m | 2,419 | 57,980 | 4.2% | |
Net worth | Rs m | 2,469 | 60,980 | 4.0% | |
Long term debt | Rs m | 0 | 15,766 | 0.0% | |
Total assets | Rs m | 4,605 | 121,924 | 3.8% | |
Interest coverage | x | NM | 18.1 | - | |
Debt to equity ratio | x | 0 | 0.3 | 0.0% | |
Sales to assets ratio | x | 1.2 | 0.5 | 274.1% | |
Return on assets | % | 5.6 | 8.8 | 63.9% | |
Return on equity | % | 10.5 | 16.4 | 63.8% | |
Return on capital | % | 17.7 | 16.8 | 105.9% | |
Exports to sales | % | 0 | 28.1 | 0.0% | |
Imports to sales | % | 0 | 18.9 | 0.0% | |
Exports (fob) | Rs m | NA | 15,506 | 0.0% | |
Imports (cif) | Rs m | NA | 10,399 | 0.0% | |
Fx inflow | Rs m | 300 | 15,506 | 1.9% | |
Fx outflow | Rs m | 2,015 | 10,399 | 19.4% | |
Net fx | Rs m | -1,715 | 5,107 | -33.6% |
CASH FLOW | |||||
---|---|---|---|---|---|
From Operations | Rs m | 88 | 11,546 | 0.8% | |
From Investments | Rs m | -94 | -7,138 | 1.3% | |
From Financial Activity | Rs m | NA | -2,417 | 0.0% | |
Net Cashflow | Rs m | -6 | 2,103 | -0.3% |
Indian Promoters | % | 0.0 | 40.4 | - | |
Foreign collaborators | % | 75.0 | 20.6 | 364.1% | |
Indian inst/Mut Fund | % | 0.3 | 8.4 | 3.6% | |
FIIs | % | 15.7 | 10.7 | 146.7% | |
ADR/GDR | % | 0.0 | 0.0 | - | |
Free float | % | 9.1 | 19.9 | 45.7% | |
Shareholders | 12,856 | 109,995 | 11.7% | ||
Pledged promoter(s) holding | % | 0.0 | 0.0 | - |
Compare ASTRAZENECA PHARMA With: J.B.CHEMICALS SUVEN LIFE SCIENCES WYETH CADILA HEALTHCARE VENUS REMEDIES
Compare ASTRAZENECA PHARMA With: ACTAVIS (US) MYLAN (US) ADCOCK INGRAM (S. Africa) TEVA PHARMA (Israel)
Indian share markets witnessed huge selling pressure today and failed to hold on to their opening gains as profit booking and weakness across all sectors erased gains.
For the quarter ended December 2020, BIOCON has posted a net profit of Rs 2 bn (down 19.7% YoY). Sales on the other hand came in at Rs 19 bn (up 5.9% YoY). Read on for a complete analysis of BIOCON 's quarterly results.
For the quarter ended September 2020, BIOCON has posted a net profit of Rs 2 bn (down 23.9% YoY). Sales on the other hand came in at Rs 17 bn (up 11.0% YoY). Read on for a complete analysis of BIOCON 's quarterly results.
For the quarter ended June 2020, ASTRAZENECA PHARMA has posted a net profit of Rs 186 m (down 13.4% YoY). Sales on the other hand came in at Rs 2 bn (down 5.4% YoY). Read on for a complete analysis of ASTRAZENECA PHARMA's quarterly results.
For the quarter ended March 2020, ASTRAZENECA PHARMA has posted a net profit of Rs 96 m (down 2.5% YoY). Sales on the other hand came in at Rs 2 bn (up 2.4% YoY). Read on for a complete analysis of ASTRAZENECA PHARMA's quarterly results.
For the quarter ended December 2019, BIOCON has posted a net profit of Rs 2 bn (up 1.2% YoY). Sales on the other hand came in at Rs 17 bn (up 13.5% YoY). Read on for a complete analysis of BIOCON 's quarterly results.
More Views on NewsIn this video, I'll show you why it might be the right time to take money of the table in pharma stocks.
The pandemic failed to thwart Richa's investing success formula for 2020.
In this video, I'll show you a crucial chart that you need to check before you decide to sell any stock or index.
Our ace stock picker is ready to capitalise on a big growth opportunity.
More